Ravi S. Narayan - Concepedia

Author

Ravi S. Narayan

Amsterdam UMC Location Vrije Universiteit Amsterdam ORCID

Also Known As

R. Narayan, R. S. Narayan, Ravi Narayan, Ravi S. Narayan

Publications

716

Citations

H-Index

Concepts

All Affiliations

Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam UMC Location University of Amsterdam Amsterdam University Medical Centers Cancer Center Amsterdam Brigham and Women's Hospital

About

Ravi S. Narayan is an author at Amsterdam UMC Location Vrije Universiteit Amsterdam specializing in medicine, glioma, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	473
2	Cell Biology	2	2	327
3	Health Sciences	1	1	97
4	Immunology	1	1	49
5	Pathology	1	1	49

Ravi S. Narayan

Publications

620

Citations

H-Index

Page 1

	Year	Citations
Human Glioma Growth Is Controlled by MicroRNA-10b Galina Gabriely, Ming Yi, Ravi S. Narayan, Cancer Research Mir-10 Family MembersMedicineTumor GrowthCancer GrowthCancer Cell Biology	2011	298
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities Ravi S. Narayan, Piet Molenaar, Jian Teng, Nature Communications Drug TargetSynergistic TargetingGliomaTumor BiologyCancer Drug Atlas	2020	97
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures Ravi S. Narayan, Carlos Alexandre Fedrigo, Eelke Brands, BMC Cancer	2017	65
The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation Nick Dekker, Tineke Voorn-Brouwer, Marri Verhoek, Blood Cells Molecules and Diseases Type 1Autoimmune DiseasePathogenesisImmunologyGaucher Disease Manifestation	2010	49
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor Elena Galvani, Jing Sun, Leticia G. León, Oncotarget	2015	31
Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma Ravi S. Narayan, Carlos Alexandre Fedrigo, Lukas J.A. Stalpers, Current Pharmaceutical Design Neuro-oncologyRadiation TherapyGliomaGlioblastoma MultiformeMedicine	2012	29
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma Ravi S. Narayan, Ana Gasol, Paul L.G. Slangen, Molecular Cancer Therapeutics	2017	26
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma Fatima Bikhezar, Robin M. de Kruijff, Astrid J.G.M. van der Meer, Journal of Neuro-Oncology	2019	25

Page 1